AZ Diabetes Portfolio vs. competitors

I guess this stellar sales performance explains the national market share for Bydureon.

I will say I am impressed. If someone can sell a drug that is the only one in its class to fail its CV outcome trial...including Tanzeum which managed to have a positive CV outcome, and still went down the tubes...AND not have samples for physicians for 6 months...kudos to you. Maybe Pascal should retire and you should take over. That's impressive.

 

Sarcasm at its best! I love it!

 

Formulary isn’t the issue. They issue is that we have 3 duds that are, at best, 3rd best in class

 

The only DUD is the marketing team. The products are great. Its just time to clean out that crew. The way they want us to sell is out dated and old fashion. Does anyone really walk into a call and just spit out a catchy tag line? That is 1990 reincarnated and it didn't work then either. We would be better off going back to leaving pens and clocks.

 

Look up az news for today. Interesting note on Teva. Hope management has a comment for the generic farxiga approval

 

October of 2020 baby.

 

No way

 

worst in class both cases!!!!!!

 

GREAT! Not

 

AZ Diabetes’ only fighting chance is almost dead. Ample time to find another job.

 

Not October 2020... We all thought that as well, but it appears that expiry is 2024

 

Wrong again. BMS owns a patent covering the composition of matter of dapagliflozin which has an expiry date of October 2020 in the US and May 2023 in the EU.
Dapagliflozin - AstraZeneca - AdisInsight
https://adisinsight.springer.com/drugs/800021756

 

BMS owns a patent covering the composition of matter of dapagliflozin which has an expiry date of October 2020 in the US and May 2023 in the EU.

 

How might additional indications affect patent length?

 

AZ will go the legal route, barter with Teva or the other generic Company, pay them a fee to hold off until a future date. This was done with Nexium when Teva got approval and was going to launch At Risk. They still could launch at risk, make some money, pay a fine and wait to go full throttle at a future date.
With generic Advair out and being marketed, there seems to be a cloud over Wilmington!!! Guess top brass was too tied up booking their SSLT trip to China and building the mother ship in the UK to worry about any of this.

 

At least Farxiga is finally the FIRST to do something! First to get a patent challenge!